Combination of PD-1 blockade and neoadjuvant chemoradiotherapy benefits pMMR/MSS patients with locally advance rectal cancer: A phase 2 clinical trial - PubMed
5 hours ago
- #immunotherapy
- #rectal cancer
- #clinical trial
- Combination of PD-1 blockade and neoadjuvant chemoradiotherapy shows promise for pMMR/MSS locally advanced rectal cancer (LARC) patients.
- The NECTAR trial reported a 40.0% pathological complete response (pCR) rate, overcoming primary resistance in pMMR/MSS tumors.
- 3-year disease-free survival (DFS) rate was 89.1%, with all pCR patients remaining DFS at 3 years.
- Patients with a low neoadjuvant rectal (NAR) score (<8) had a 100% 3-year DFS rate.
- No new grade ≥III treatment-related adverse events (trAEs) occurred during the 3-year follow-up.
- The trial demonstrates promising efficacy and safety, offering a new therapeutic avenue for traditionally resistant patients.